PropertyValue
?:abstract
  • PURPOSE OF REVIEW: This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19. RECENT FINDINGS: It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied. SUMMARY: Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.
?:creator
?:doi
  • 10.1007/s11892-020-01366-0
?:doi
?:journal
  • Curr_Diab_Rep
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/3a5caee47790cced4e7002214d2fa6f8d79d041e.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7690847.xml.json
?:pmcid
?:pmid
?:pmid
  • 33244614.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
?:type
?:year
  • 2020-11-26

Metadata

Anon_0  
expand all